Biotech Values

[oc631]

What makes this speculation worth thinking about is that GILD’s phase-3 dataset doesn’t clearly make the case for an 8-week duration for all treatment-naïve non-cirrhotic patients

I think you are making a valid case about GILD's application. Some may counter by saying the Sovaldi backbone has already gained approval and the ABBV combo has more moving parts. None of which have achieved approval (yet).